Summer 2026
Posted on 3/24/2026
Professional networking, residency tools, telehealth
No salary listed
San Francisco, CA, USA
Hybrid
Three days on-site per week in SF (Mon/Tue/Thu).
Bachelor's
| , |
See people who can refer or advise you
Doximity is a digital platform for United States healthcare professionals, offering a professional social network, a residency navigator, and telehealth services. Users join to connect with peers, share medical insights, track residency applications, and conduct remote patient visits. Revenue comes from targeted advertising to medical professionals, premium subscriptions, and telehealth usage fees. Its goal is to improve communication and collaboration among clinicians, support career development and residency placement, and expand access to care through convenient telehealth.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Family Planning Benefits
Paid Vacation
Paid Holidays
Wellness Program
Penn Highlands Healthcare partners with Doximity to launch system-wide clinical AI suite. Penn Highlands Healthcare has adopted Doximity's clinical AI suite, Doximity Dialer, Doximity Ask, and Doximity Scribe, across its nine hospitals, replacing a patchwork of separate tools with a single set that handles patient calls, clinical questions, and visit documentation. For a system that has served Pennsylvania communities for more than a century, the logic is simple: give clinicians technology that works at the point of care without pulling their attention away from the patient in front of them. What the clinical teams get. Doximity Dialer, a secure, HIPAA-compliant telehealth platform, lets staff call patients from any device while showing a verified Penn Highlands number on caller ID, with no downloads or logins for patients to join a video visit. Doximity Ask is a HIPAA-compliant clinical AI, purpose-built for medicine, giving clinicians verified answers at the point of care and handling the documentation and administrative work that should not be consuming their day. An independent Stanford/Harvard study ranked it highest for safety among U.S. clinical AI tools. Doximity Scribe is an ambient AI documentation assistant that generates notes during in-person and virtual visits, giving physicians back time for face-to-face conversation with patients. Why it matters to Penn Highlands. "Doximity offers tailored ways to optimize search output and streamline processes for our entire system," said Russell Cameron, MD, chief medical information officer for Penn Highlands Healthcare. "By bringing these new technologies together under a unified platform, Penn Highlands Healthcare continues to modernize its care delivery framework. This partnership ensures clinicians spend less time navigating software and more time focused on delivering personalized, high-quality care to patients across the region." The system-wide adoption reflects how health systems are approaching clinical technology today. "Penn Highlands Healthcare's decision to adopt Doximity's AI-powered clinical tools across nine hospitals reflects a broader shift of health systems moving to fewer, vetted and trusted tools, not a patchwork of point solutions," said Aaron Kornetzke, general manager of enterprise solutions at Doximity. "We're proud to help their physicians be more productive and deliver better care to their patients."
Timothy Cabral, a director at Doximity, sold 7,500 shares of Class A Common Stock on 7 August through a pre-arranged Rule 10b5-1 trading plan adopted in February. The sale occurred the day after Doximity's stock jumped 33% following earnings, though the timing was automatic rather than discretionary. The transaction reduced Cabral's direct holdings to 3,221 shares, but he retains 326,000 derivative securities. Doximity reported revenue of $156.6 million for the quarter, up 7%, whilst free cash flow fell 34% to $39.6 million. The company attributed the decline to accounts receivable timing. Doximity operates a cloud-based platform for healthcare practitioners and generates revenue through subscriptions from pharmaceutical companies and healthcare organisations. The stock had declined 50% over the prior year before the recent surge.
Doximity's Chief Accounting Officer Siddharth Sitaram disposed of 5,652 shares for $140,400 on 13 and 15 August, according to an SEC Form 4 filing. The transaction was non-discretionary and tax-related. It consisted of 3,882 shares withheld by the issuer to cover restricted stock unit vesting and 1,770 shares sold under a Rule 10b5-1 plan to satisfy tax obligations from an option exercise. Following the transaction, Sitaram maintains direct ownership of 93,122 shares and holds 59,000 derivative securities, with a post-transaction value of $2.31 million. Doximity operates a cloud-hosted digital platform for healthcare practitioners. The company reported trailing 12-month revenue of $655.6 million and net income of $167.0 million, with a market capitalisation of $4.6 billion.
Dutch Bros, the US coffee chain, is attracting attention for its strong same-store sales performance and expansion strategy. The company has achieved average same-store sales growth of 6% over the past two years and expects revenue growth of 27.7% for the next year. Meanwhile, two cash-generating companies face challenges. Doximity, the physician networking platform, has seen costs rise faster than revenue, with operating margins declining by 10.5 percentage points. Its estimated sales growth of 4.6% for the next 12 months suggests slowing demand. Silgan Holdings, the packaging supplier, has experienced annual revenue growth of just 4.7% over five years and earnings per share growth of only 2.4% annually.
Doximity reported Q2 revenue of $156.6 million, up 7.3% year on year and beating analyst estimates of $151.3 million. The medical professional network's adjusted earnings per share of $0.29 missed expectations by 4.2%. The company attributed growth to increased adoption of AI-powered clinical tools. CEO Jeffrey Tangney noted quarterly active workflow prescribers grew more than 30% year on year, with nearly half using AI tools. Operating margin declined to 21.5% from 37.4% in the prior year period. The company raised full-year revenue guidance to $676 million from $670 million but set EBITDA guidance below analyst estimates at $319 million. CFO Matthew Sonefeldt said higher AI usage prompted increased investment to capture long-term opportunities, explaining near-term margin pressure.